Re F "personally I think they would be crazy not to raise capital again at these levels" 30 million in cash, plus option exercise money, another $5million minimum
A Big Pharma licensing/partnership deal for HerVaxx on its own would be in excess of Us$1 billion face value in upfront and milestone fees Retaining 15% as drip feed working capital to fund additional pipeline trials, and pay a special dividend to shareholders would ensure a cap raise in the traditional manner ,will not happen for quite some time.
Ditto for Pd1 vaxx mid Ph2 .
Ditto for CF33 ....at a much higher face value.
Money in the bank gathers data, data generates more deals, deals generate growth and value.
The market sees it , hence the massive re rate underway.
(20min delay)